<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35357690</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2199-1154</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drugs - real world outcomes</Title>
          <ISOAbbreviation>Drugs Real World Outcomes</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Estimating the National Population of Hospitalized Chronic Baclofen Users: A Cross-Sectional Analysis of a Commercial Claims Database.</ArticleTitle>
        <Pagination>
          <StartPage>307</StartPage>
          <EndPage>314</EndPage>
          <MedlinePgn>307-314</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40801-022-00293-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Baclofen is an effective treatment for spasticity. Abrupt cessation of intrathecal (IT) or oral baclofen risks the development of withdrawal symptoms; however, the magnitude of the problem is unknown.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aims for this study were as follows: (1) using an administrative claims database, estimate the number of patients in the United States on baclofen, and (2) estimate the annual percent hospitalized pediatric and adult populations consequently at risk for interruption of chronic baclofen therapy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Using 2011-2014 data representing commercially insured individuals, patients were selected based on insurance coverage; evidence of a baclofen claim; and hospitalization. All patients hospitalized while receiving chronic baclofen were assumed to be at risk for baclofen discontinuation. Yearly counts were determined and then extrapolated to national estimates using census data.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Extrapolating from the claims database, oral or IT baclofen was prescribed annually to 33,061 or 1486 patients ≤ 18 years, and 654,294 or 7084 patients 19-64 years, respectively. The estimated national mean number of at-risk hospitalizations per year for patients aged 19-64 years on chronic oral or IT baclofen was 31,116 and 3774, respectively; patients ≤ 18 years numbered 4691 and 959, respectively. The mean percent of patients hospitalized per year was 42% in those ≤ 18 years receiving IT baclofen compared with 30% in adults, and 3-10% in the populations receiving oral baclofen.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extrapolation from an administrative claims database was used to estimate the national number and demographics of hospitalized chronic baclofen users. Patients ≤ 18 years receiving IT baclofen were at highest risk of withdrawal due to a high occurrence of hospitalization.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schmitz</LastName>
            <ForeName>Natalie</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-4229-919X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA. Natalie.schmitz@wisc.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, University of Wisconsin, 1037 Rennebohm, Hall 777 Highland Ave, Madison, WI, 53705, USA. Natalie.schmitz@wisc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Artz</LastName>
            <ForeName>Margaret</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Optum, Eden Prairie, MN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Blackstone Artz Solutions LLC, Minneapolis, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walsh</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Optum, Eden Prairie, MN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Population Health, Thomas Jefferson University, 901 Walnut, St. Philadelphia, PA, 19107, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gaudana</LastName>
            <ForeName>Sandeep</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Optum, Eden Prairie, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cloyd</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schrogie</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Allaysis LLC, Marlton, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kriel</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drugs Real World Outcomes</MedlineTA>
        <NlmUniqueID>101658456</NlmUniqueID>
        <ISSNLinking>2198-9788</ISSNLinking>
      </MedlineJournalInfo>
      <CoiStatement>This study was primarily funded by contracts from Allaysis, LLC awarded to the University of Minnesota and to Optum. Should the investigational intravenous baclofen formulation being developed by Allaysis LLC be commercialized, the University of Minnesota and James Cloyd may receive royalty payments.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>12</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35357690</ArticleId>
        <ArticleId IdType="pmc">PMC9114172</ArticleId>
        <ArticleId IdType="doi">10.1007/s40801-022-00293-8</ArticleId>
        <ArticleId IdType="pii">10.1007/s40801-022-00293-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>McKesson, Baclofen Tablet Package Insert. 2013. p. 1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Medtronic, Full Prescribing Information about ITB Therapy LIORESAL® INTRATHECAL (baclofen injection). 2013. p. 1–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Hasnat MJ, Rice JE. Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cochrane Database Syst Rev. 2015;11:CD004552.</Citation>
        </Reference>
        <Reference>
          <Citation>Korenkov AI, et al.  Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. Neurosurg Rev. 2002;25(4):228–230. doi: 10.1007/s10143-002-0221-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10143-002-0221-1</ArticleId>
            <ArticleId IdType="pubmed">12172730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil. 1996;77:461–466. doi: 10.1016/S0003-9993(96)90034-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0003-9993(96)90034-9</ArticleId>
            <ArticleId IdType="pubmed">8629922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palpacuer C, et al.  Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220–237. doi: 10.1111/add.13974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/add.13974</ArticleId>
            <ArticleId IdType="pubmed">28940866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck A, et al.  Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. Eur Neuropsychopharmacol. 2018;28(11):1206–1216. doi: 10.1016/j.euroneuro.2018.08.507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2018.08.507</ArticleId>
            <ArticleId IdType="pubmed">30217552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 2017;8(8):CD008502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6483686</ArticleId>
            <ArticleId IdType="pubmed">28822350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minozzi S, Saulle R, Rösner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018;11(11):CD012557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6517285</ArticleId>
            <ArticleId IdType="pubmed">30484285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitz NS, et al.  A randomized dose escalation study of intravenous baclofen in healthy volunteers: clinical tolerance and pharmacokinetics. PM R. 2017;9(8):743–750. doi: 10.1016/j.pmrj.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pmrj.2016.11.002</ArticleId>
            <ArticleId IdType="pubmed">27867020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green L, Nelson V. Death after acute withdrawal of intratehcal baclofen: case report and literature review. Arch Phys Med Rehabil. 1999;80:1600–1604. doi: 10.1016/S0003-9993(99)90337-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0003-9993(99)90337-4</ArticleId>
            <ArticleId IdType="pubmed">10597813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffey RJ, et al.  Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735–741. doi: 10.1053/apmr.2002.32820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/apmr.2002.32820</ArticleId>
            <ArticleId IdType="pubmed">12048649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ross JC, et al.  Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care. 2011;14(1):103–108. doi: 10.1007/s12028-010-9422-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12028-010-9422-6</ArticleId>
            <ArticleId IdType="pubmed">20717751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meleger AL. Muscle relaxants and antispasticity agents. Phys Med Rehabil Clin N Am. 2006;17(2):401–413. doi: 10.1016/j.pmr.2005.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pmr.2005.12.005</ArticleId>
            <ArticleId IdType="pubmed">16616274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner MR, Gainsborough N. Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen. J Psychopharmacol. 2001;15(1):61–63. doi: 10.1177/026988110101500111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/026988110101500111</ArticleId>
            <ArticleId IdType="pubmed">11277611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolaski K, Logan LR. A review of the complications of intrathecal baclofen in patients with cerebral palsy. NeuroRehabiliation. 2007;22:383–395. doi: 10.3233/NRE-2007-22505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/NRE-2007-22505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsh N, et al.  Observational study of peripheral intravenous catheter outcomes in adult hospitalized patients: a multivariable analysis of peripheral intravenous catheter failure. J Hosp Med. 2018;13:83–89. doi: 10.12788/jhm.2867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12788/jhm.2867</ArticleId>
            <ArticleId IdType="pubmed">29073316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zingg W, Pittet D. Peripheral venous catheters: an under-evaluated problem. Int J Antimicrob Agents. 2009;34(Suppl 4):S38–42. doi: 10.1016/S0924-8579(09)70565-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0924-8579(09)70565-5</ArticleId>
            <ArticleId IdType="pubmed">19931816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lederle FA, et al.  The idle intravenous catheter. Ann Intern Med. 1992;116(9):737–738. doi: 10.7326/0003-4819-116-9-737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-116-9-737</ArticleId>
            <ArticleId IdType="pubmed">1558345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malach T, et al.  Prospective surveillance of phlebitis associated with peripheral intravenous catheters. Am J Infect Control. 2006;34(5):308–312. doi: 10.1016/j.ajic.2005.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajic.2005.10.002</ArticleId>
            <ArticleId IdType="pubmed">16765211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritchie S, Jowitt D, Roberts S. The Auckland City Hospital Device Point Prevalence Survey 2005: utilisation and infectious complications of intravascular and urinary devices. N Z Med J. 2007;120(1260):U2683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17726497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waitt C, Waitt P, Pirmohamed M. Intravenous therapy. Postgrad Med J. 2004;80(939):1–6. doi: 10.1136/pmj.2003.010421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/pmj.2003.010421</ArticleId>
            <ArticleId IdType="pmc">PMC1757963</ArticleId>
            <ArticleId IdType="pubmed">14760169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pujol M, et al.  Clinical epidemiology and outcomes of peripheral venous catheter-related bloodstream infections at a university-affiliated hospital. J Hosp Infect. 2007;67(1):22–29. doi: 10.1016/j.jhin.2007.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhin.2007.06.017</ArticleId>
            <ArticleId IdType="pubmed">17719678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tager IB, et al.  An epidemiologic study of the risks associated with peripheral intravenous catheters. Am J Epidemiol. 1983;118(6):839–851. doi: 10.1093/oxfordjournals.aje.a113702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a113702</ArticleId>
            <ArticleId IdType="pubmed">6650485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin GA, et al.  Physician-delivered malnutrition: why do patients receive nothing by mouth or a clear liquid diet in a university hospital setting? JPEN J Parenter Enteral Nutr. 2011;35(3):337–342. doi: 10.1177/0148607110374060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0148607110374060</ArticleId>
            <ArticleId IdType="pubmed">21383319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FBD MedKnowledge. https://www.fdbhealth.com/fdb-medknowledge/.</Citation>
        </Reference>
        <Reference>
          <Citation>Alvis BD, Sobey CM. Oral baclofen withdrawal resulting in progressive weakness and sedation requiring intensive care admission. Neurohospitalist. 2017;7(1):39–40. doi: 10.1177/1941874416637404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1941874416637404</ArticleId>
            <ArticleId IdType="pmc">PMC5167087</ArticleId>
            <ArticleId IdType="pubmed">28042369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leo RJ, Baer D. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies. Psychosomatics. 2005;46(6):503–507. doi: 10.1176/appi.psy.46.6.503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.psy.46.6.503</ArticleId>
            <ArticleId IdType="pubmed">16288128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC Wonder. https://wonder.cdc.gov/controller/datarequest/D7;jsessionid=04D11D0171CC096FE53A6992042928FC.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmitz NS, et al.  Characterizing baclofen withdrawal: a national survey of physician experience. Pediatr Neurol. 2021;122:106–109. doi: 10.1016/j.pediatrneurol.2021.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pediatrneurol.2021.06.007</ArticleId>
            <ArticleId IdType="pubmed">34330615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal SK, et al.  A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. J Child Neurol. 2015;30(1):37–41. doi: 10.1177/0883073814535504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073814535504</ArticleId>
            <ArticleId IdType="pubmed">25028414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scherkenbach LA, et al.  Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study. J Pharm Pharmacol. 2014;66(7):935–942. doi: 10.1111/jphp.12221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jphp.12221</ArticleId>
            <ArticleId IdType="pubmed">24697865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krach LE, et al.  Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model. J Pediatr Rehabil Med. 2011;4(2):89–98. doi: 10.3233/PRM-2011-0160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/PRM-2011-0160</ArticleId>
            <ArticleId IdType="pubmed">21955965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Personal Communication, Medtronic Inc. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Orphan Drug Act of 1983. U.F.a.D. Administration, Editor. 1983.</Citation>
        </Reference>
        <Reference>
          <Citation>Population Projections, United States, 2004–2030, by state, age and sex, on CDC WONDER Online Database. 2005 April 6, 2020]. http://wonder.cdc.gov/population-projections.html.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
